InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.12
(
-0.01%
)
Bitcoin
63,890.20
(
-0.16%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: EyeamBill post# 103063

Thursday, 09/02/2010 11:02:24 PM

Thursday, September 02, 2010 11:02:24 PM

Post# of 251721

MNTA—are glycoprotein IIb/IIIa products in play?

They could be. Integrilin would seem to be a good candidate for MNTA’s technology insofar as it’s hard to copy (and hence attractive to MNTA from a competitive standpoint) while also being regulated by the FDA as a small-molecule drug, which allows a generic to be fully substitutable for the branded product. The Integrilin patents in the Orange Book expire in 2014-2015.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up